Immunosuppression and reactivation of hepatitis B in the lamivudine era: opportunities for prevention and exploitation?
Farrell
G C
GC
D000998:Antiviral Agents / Q000627:therapeutic use*; D006513:Hepatitis B e Antigens / Q000032:analysis; D006515:Hepatitis B virus / Q000254:growth & development* / Q000276:immunology; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D006801:Humans; D007108:Immune Tolerance; D019259:Lamivudine / Q000627:therapeutic use*; D012008:Recurrence; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D014775:Virus Activation
D000998:Antiviral Agents; D006513:Hepatitis B e Antigens; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine